Funobactam(XNW4107) is a new type of β-lactamase inhibitor. The preclinical trial data show that the drug has strong lethality to gram-negative bacteria, and has the simultaneous effect on acinetobacter baumannii, pseudomonas aeruginosa and enterobacteriaceae. Its bacteriostatic effect is better than that of similar products on the market or in clinical stage. 

January 15, 2021, FDA approved QIDP (qualified infectious drug product) and FTD (fast track design) of Funobactam(XNW4107), a new generation β- The lactamase inhibitor (BLI) of Sinovent for two indications of cUTI (complex urinary tract infection) and HABP/VABP (hospital or ventilator-acquired pneumonia).